Muhammed Fatih TABARA, Sevda KORKMAZ, Sema BAYKARA, Murat ATMACA

Klomipraminin neden olduğu akut distoni: Bir olgu sunumu

İlaç kullanımıyla ortaya çıkan akut distoni, etiyolojisinde birçok ilacın olduğu ama en sık nöroleptiklerle ortaya çıkan bir hareket bozukluğudur. Antidepresan kullanımı ile ortaya çıkan ekstrapiramidal yan etkilerin oluş mekanizması tam olarak bilinmemektedir. Ancak, dopaminerjik fonksiyonların nigrostriatal yolakta inhibe edilmesi, dopaminerjik, serotonerjik, noradrenerjik veya kolinerjik aktivite arasındaki dengenin bozulması, striatumda dopaminerjik fonksiyonların serotonin tarafından inhibisyonunun ekstrapiramidal yan etkilere yol açması ileri sürülen hipotezlerdendir. Literatürde klomipramin kullanımı sonrasında akut distoni gelişen vaka sayısı nadirdir. Biz 19 yaşındaki erkek hastamızda klomipramin kullanımının 5. gününde ortaya çıkan akut distoni gelişimi olgusunu sunarak klomipraminin nadir görülen bu yan etkisine dikkat çekmek ve literatüre katkıda bulunmak istedik.

Acute Dystonia Caused by Clomipramine: a Case Report

Drug-induced acute dystonia is a movement disorder that occurs most often with neuroleptics, thoughthere are many drugs in its etiology. The exact mechanism of antidepressant-associated extrapyramidalside effects (EPS) is not known. However, hypotheses including inhibition of dopaminergic function inthe nigrostriatal pathway, impaired balance between dopaminergic, serotonergic, noradrenergic orcholinergic activity, and serotonergic inhibition of dopaminergic functions in the striatum leading toextrapyramidal side effects have been suggested. The number of cases with acute dystonia duringclomipramine use is low. We wish to draw attention to this rare side effect of clomipramine and tocontribute to the literature by presenting a case of acute dystonia on the 5 th day of clomipraminetreatment in a 19-year-old male patient.

PDF

___

Ozturk MO. Mental Health and Mental Disorders. Ankara: Nobel Medicine Bookstores, 2015. (Turkish)
Domínguez-Morán JA, Callejo JM, Fernández-Ruiz LC, Martínez-Castrillo JC. Acute paroxysmal dystonia induced by fluoxetine. Mov Disord 2001; 16:767-769. [CrossRef]
Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17:377-389. [CrossRef]
Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants – a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010; 22:148-156.
Schillevoort I, van Puijenbroek EP, de Boer A, Roos RA, Jansen PA, Leufkens HG. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case control study using spontaneous reports. Int Clin Psychopharmacol 2002; 17:75-79. [CrossRef]
Najjar E, Price LH. Citalopram and dystonia. J Am Acad Child Adolesc Psychiatry 2004; 43:8-9. [CrossRef]
Baykara S, Korkmaz S, Taşcı G, Kaya S, Atmaca M. Edema induced with clomipramine. Journal of Mood Disorders (JMOOD) 2016; 6:238-241. [CrossRef] (Turkish)
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Fifth ed., Washington DC: American Psychiatric Pub., 2013.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245. [CrossRef]
Hedenmalm K, Guzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26:192- 197. [CrossRef]
Shin HW, Chung SJ. Drug induced parkinsonism. J Clin Neurol 2012; 8:15-21. [CrossRef]
Robottom BJ, Shulman LM, Weiner W.J. Drug-induced movement disorders: emergencies and management. Neurol Clin 2012; 30:309-320. [CrossRef]
Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord 2011; 26:2226-2231. [CrossRef]
Cunningham Owens DG. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge: Cambridge University Press, 1999. [CrossRef]
Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005; 28:191- 208. [CrossRef]
Baykara, S. Oromandibular dystonia with sertraline treatment: a case report. Anatolian Journal of Psychiatry 2017; 18(Suppl.1):59- 61. [CrossRef]
Sproule BA, Naranjo CA, Bremmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997; 33:454471. [CrossRef]
Stahl SM. Essential Psychopharmacology Neuroscientific Basis and Practical Applications Second Ed. Cambridge: Cambridge University Press; 2000.
Foster AR, Lancaster NP. Disturbance of motor function during treatment with imipramine. Br Med J 1959; 2:1452-1453. [CrossRef]
Chithiramohan RN, Ballard CG, Measey LG. Acute dystonia induced by clomipramine therapy. Ir J Psychol Med 1990; 7:141- 142. [CrossRef]
Starkey SR, Morrisey JK, Hickam HD, Albright JD, Lynch MJ. Extrapyramidal side effects in a blue and gold macaw (Ara ararauna) treated with haloperidol and clomipramine. J Avian Med Surg 2008; 22:234-239. [CrossRef]
van Harten PN, Hoek WH, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999; 319:623-626. [CrossRef]